Conformational adaptation in drug-target interactions and residence time.
about
Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme–Product ComplexA structural and energetic model for the slow-onset inhibition of the Mycobacterium tuberculosis enoyl-ACP reductase InhA.Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1LKinetic analysis of drug-protein interactions by affinity chromatographyTowards structural systems pharmacology to study complex diseases and personalized medicineThe use of thermodynamic and kinetic data in drug discovery: decisive insight or increasing the puzzlement?Time-resolved crystallography using the Hadamard transformRaTrav: a tool for calculating mean first-passage times on biochemical networks.Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approachDefinition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitorsRadioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems.Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics.Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.Drug-target residence time--a case for G protein-coupled receptors.Ligand-detected relaxation dispersion NMR spectroscopy: dynamics of preQ1-RNA binding.The impact of binding thermodynamics on medicinal chemistry optimizations.On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.Flexible receptor docking for drug discovery.The drug-target residence time model: a 10-year retrospective.On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targetsDrug-target interaction kinetics: underutilized in drug optimization?Advanced molecular dynamics simulation methods for kinase drug discovery.TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy.Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivoConformational energy range of ligands in protein crystal structures: The difficult quest for accurate understanding.Cathepsin B Inhibitors: Combining Dipeptide Nitriles with an Occluding Loop Recognition Element by Click Chemistry.High performance enzyme kinetics of turnover, activation and inhibition for translational drug discovery.Evolution and intelligent design in drug development.Resistance mechanism to an uncompetitive inhibitor of a single-substrate, single-product enzyme: a study of Helicobacter pylori glutamate racemase.Drug-Target Kinetics in Drug Discovery.Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics.'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.Discrimination between conformational selection and induced fit protein-ligand binding using Integrated Global Fit analysis.Correlating Drug-Target Kinetics and In vivo Pharmacodynamics: Long Residence Time Inhibitors of the FabI Enoyl-ACP Reductase.Toward High-Throughput Predictive Modeling of Protein Binding/Unbinding Kinetics.An explicit-solvent conformation search method using open software.How and when does an anticancer drug leave its binding site?
P2860
Q27670966-640A4510-B089-4D3B-9247-A0DB7F546334Q27678258-477F2633-AABA-4C84-950F-B01D5FD73EAEQ27681724-8D64452D-1B75-4E77-A836-DCAA0912777EQ27682251-5B16FBD9-48AA-4510-A95C-28D268FD3F4EQ28069746-37F20E24-1F0C-47A2-9A69-6AEE46D55F34Q28538838-BEAF3F19-4A4B-4244-BE8F-DFF3DA366669Q30881748-9087D2EF-CD9A-4178-A19A-45684D7C56E4Q34441775-C97EF590-7614-4810-B4C7-BDA22DAF7DE6Q35049861-AFAF3AA0-A998-4734-BEEB-AC35AA889431Q36220942-9353AF6F-540E-4451-B125-AA42EC7ED7AAQ36327175-5788C731-4D7E-4AF7-864E-9AB2733321EEQ36493862-CB12589B-0FD5-4771-95FC-201F2C5BC032Q38014940-86AC4A52-0B8B-4714-B661-6EF8D51C5F89Q38060521-1D13B1E9-D838-4BD8-8777-B88175DB8A67Q38075043-FA960C6D-BA7E-4876-B174-ED4785A1950FQ38189272-1943AE5E-8001-4B19-B29D-94EDD6CCBA30Q38303011-8E887349-6022-41F4-942A-D0FF53D7D721Q38542936-674932DB-E367-46C8-89F4-664FF6D59BD0Q38545579-689EFED2-2361-47AC-A683-E0A1CE73C087Q38574930-9B86F6C8-41C4-4FD4-87CA-B952E0283EBFQ38672210-94C36401-C8DB-410B-B5BF-D7ADB2B87CD2Q38710840-C5EB260A-E898-4979-B650-E34A38BDBA1BQ38795292-EFB070C9-2100-42C2-BDDB-89EEC9582120Q38800768-7F2891C1-F20F-4DE6-AA64-D52A1B26182FQ38805094-B7A1241D-9D97-4E0E-A0BE-380490ADA0BEQ38822818-29F4CC29-D3AD-4BB7-8E6A-D192A80C7AE4Q38944603-7537DD91-FD5B-4405-8464-6EA412D03E0CQ38966313-1A404725-0549-439D-AE80-EF779188B10AQ38991583-C6427F72-A4CF-41C6-B46B-189F5CF32877Q38998249-B305157E-AFFE-4503-81A4-449253E61349Q39383708-8BA6ABB4-9465-472F-9C0D-23586924BE4EQ39391104-706637CE-0B57-4A11-86F2-691140A3C5BCQ39780387-A8D8D976-6A12-4B15-A0D0-78F8AF17BDC6Q39786582-5D712B1E-8A09-4590-A864-2D20C9FE8CECQ40322173-40F3828D-F5F2-428B-B917-B43A109523D6Q40354631-891ABDBB-E4A6-4C53-B639-433EE587AB90Q40567992-111794BD-25D5-4A11-B134-9B8CFD76F25BQ41190100-6A54178B-D9A9-478B-BB35-DDEC48DC3C3AQ41947634-2DDFF600-20B1-4979-9FB4-410BE8E5F9F4Q41965081-E3819A03-1967-4B6A-B5BD-24231618ACF3
P2860
Conformational adaptation in drug-target interactions and residence time.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Conformational adaptation in drug-target interactions and residence time.
@en
Conformational adaptation in drug-target interactions and residence time.
@nl
type
label
Conformational adaptation in drug-target interactions and residence time.
@en
Conformational adaptation in drug-target interactions and residence time.
@nl
prefLabel
Conformational adaptation in drug-target interactions and residence time.
@en
Conformational adaptation in drug-target interactions and residence time.
@nl
P2860
P356
P1476
Conformational adaptation in drug-target interactions and residence time.
@en
P2093
Robert A Copeland
P2860
P304
P356
10.4155/FMC.11.112
P577
2011-09-01T00:00:00Z